Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool December 4, 2009 Brian Orelli	Our Final Offer (Maybe)! That's a FACT! Biogen ups its bid for Facet.
The Motley Fool September 4, 2009 Brian Orelli	Takeover Likely? Management Says No! A hostile bid that management didn't want. Biogen Idec announced today that it's willing to buy Facet Biotech for $14.50 per share.
The Motley Fool June 29, 2010 Brian Orelli	Redeploying Capital? Investors Hope So. Selling a business unit won't help Abbott Labs diversify.
The Motley Fool April 22, 2010 Brian Orelli	Abbott's Stuck in a Double-Digit Rut The company keeps cranking out solid earnings, but investors don't seem to care.
The Motley Fool November 13, 2009 Brian Orelli	Abbott: Brave or Stupid? Abbott Labs announces the acquisition of PanGenetics' pain drug PG110, which is still in phase 1 trials.
The Motley Fool December 16, 2009 Brian Orelli	No Holiday Goodwill Twixt Biogen and Facet Biogen and Facet are still at it, as their nasty takeover fight continues.
The Motley Fool August 3, 2005 Charly Travers	Biotech's Big Deal The market is pleased with the partnership between Protein Design Labs and Biogen IDEC.
The Motley Fool October 15, 2007 Brian Lawler	PDL BioPharma's Best Hope The data on daclizumab for multiple sclerosis is encouraging. Investors, take note.
The Motley Fool October 7, 2008 Brian Orelli	Eli Lilly's Risky Gamble Eli Lilly is desperate, and the high acquisition price of ImClone shows it.
The Motley Fool July 26, 2006 Brian Lawler	Biogen Slows Down Several potential growth drivers should help the biopharma. Ever since the merger with Idec, the company has been fairly well run (absent the Tysabri delays). Investors, take note.
The Motley Fool June 16, 2010 Brian Orelli	Double-Digit Rise on Doubling Its Cash Neurocrine Biosciences is seeing a nice boost to its stock price today -- some 14% -- after Abbott Labs agreed to license its endometriosis treatment, elagolix, and any future follow-on products.
The Motley Fool February 10, 2010 Brian Orelli	Icahn's Smiling -- Should We Be? Biogen Idec's fourth quarter results must have made Carl Icahn smile. But the guidance for next year gives pause.
The Motley Fool October 16, 2007 Brian Lawler	Questions Surround a Biogen Deal Rumors swirl around Biogen after it publicly announces that it's for sale. Investors, take note.
The Motley Fool September 24, 2010 Brian Orelli	Good Deal? Bad Deal? Hard to Tell. Investors are in the dark on Abbott Labs' license of Reata Pharmaceuticals' kidney failure drug bardoxolone for $450 million up front.
The Motley Fool March 8, 2005 Charly Travers	After the Crash, Is Biogen IDEC a Buy? Biogen stock plunge may be an overreaction to pulling multiple sclerosis drug Tysabri off the market.
The Motley Fool September 28, 2009 Rick Aristotle Munarriz	Abbott Labs Looks Less Lopsided Abbott Labs' $6.6 billion purchase of Solvay's pharmaceuticals business is just what the doctor ordered.
The Motley Fool August 28, 2009 Brian Orelli	Abbott Signs Up Another One Abbott announces that it has set up a partnership with Pfizer to run tests on Pfizer's new drug.
The Motley Fool December 13, 2007 Brian Lawler	Biogen Can't Find a Buyer After formally putting itself up for sale two months ago, Biogen Idec announces that it can't find any takers.
The Motley Fool January 29, 2008 Brian Lawler	Icahn Tries to Board USS Biogen Carl Icahn and the funds that he runs announce that they will try to get elected to three seats on the board of directors at Biogen Idec.
The Motley Fool May 2, 2007 Brian Lawler	Biogen's Measured Growth The biopharmaceutical reports first-quarter financial results. Investors, take note.
The Motley Fool July 29, 2010 Brian Orelli	Is Abbott a Buy? Whether or not Abbott is a buy depends on management's ability to transition the company.
The Motley Fool January 28, 2010 Brian Orelli	The Biggest Development-Stage Drugmaker, Ever Eli Lilly seems to have a lot more in common with its development-stage little brothers than it does with its big pharma brethren.
The Motley Fool January 27, 2011 Brian Orelli	Abbott Labs: Growth in All the Wrong Places Abbott's a solid company with solid dividend and growth potential in the near term. But investors need to be careful extrapolating that growth out.
The Motley Fool July 21, 2010 Brian Orelli	Biogen Looks Good Now, but What About Tomorrow? Biogen Idec saw revenue increase 11% and adjusted earnings per share jump almost 75%, which is all well and good, but the longer-term prospects for the company aren't nearly as impressive.
The Motley Fool June 8, 2010 Ryan McBride	Biogen's CEO Retires, COO to Follow A replacement won't be announced for a few weeks.
The Motley Fool May 18, 2010 Brian Orelli	What Astellas' Purchase of OSI Means for Biotech Investors Stop buying for the potential takeout.
The Motley Fool July 23, 2008 Brian Lawler	No Picking at Biogen At a time in which all of its top drugs experienced at least double-digit percentage sales growth, there aren't many issues to poke at with Biogen Idec's just-released second-quarter financial results.
The Motley Fool April 22, 2011 MedCity News	Biogen Idec's MS Drug Appears to Have an Edge Trial results give the company an advantage in oral MS treatments.
The Motley Fool September 14, 2006 Brian Lawler	Good Buy for Biogen Idec The biotech's past success bodes well for its plans for a new blood pressure drug. Investors, take note.
The Motley Fool April 12, 2004 Brian Gorman	Abbott Not Rewarded Abbott Laboratories first-quarter earnings news was positive, but investors didn't react enthusiastically.
The Motley Fool July 13, 2005 Stephen D. Simpson	Is Abbott's Ailment Serious? There's room for improvement at Abbott Labs, but this is one solid and broadly diversified company. Shares aren't a screaming bargain, but the current price-to-earnings ratio really isn't out of line with history.
The Motley Fool October 20, 2011 Brian Orelli	Mini J&J? I Guess Not Abbott says it plans to split in two: drugs in one company, everything else in the other.
The Motley Fool August 10, 2011 Brian Orelli	A Jab a Month Is All We Ask Biogen and Abbott's new long-acting multiple sclerosis drug works, but it has side effects.
The Motley Fool June 30, 2010 Ryan McBride	Reports: Biogen Picks Exelixis Chief George Scangos as New CEO George Scangos, a microbiologist by training, has been CEO of the South San Francisco-based cancer drug developer Exelixis since 1996, and takes over at Biogen immediately.
The Motley Fool April 28, 2008 Brian Lawler	Bristol-Myers' Comeback Continues The pharmaceutical's first quarter brings more robust results.
The Motley Fool August 19, 2010 Brian Orelli	High Risk, High Reward. At Least It Was Cheap! Biogen licenses a drug to treat ALS.
The Motley Fool March 16, 2007 Brian Lawler	PDL's Friend Comes Through PDL and partner Biogen advance one of their lead drug candidates. Investors, take note.
The Motley Fool December 10, 2009 Brian Orelli	A Tale of Two Lillys It was the best of times, it was the worst of times. Dickens could have been talking about Eli Lilly which has a tale of two cities all on its own.
The Motley Fool February 8, 2005 Charly Travers	Good Prognosis for Biogen IDEC Blockbuster products help the biotech firm continue its stellar performance.
The Motley Fool June 11, 2009 Brian Orelli	The FTC Hates You, Too The agency weighs in (unhappily) on follow-on biologics.
The Motley Fool June 29, 2011 Brian Orelli	Doubling Up in Biotech Lilly hits multiple targets with one drug.
The Motley Fool February 6, 2009 Brian Orelli	Icahn vs. Biogen: Round 2 On the heels of an announcement that he'll try to get seats on Amylin Pharmaceuticals' board, Icahn is also angling for seats on Biogen Idec's board.
The Motley Fool June 30, 2010 Brian Orelli	Is Bristol-Myers Squibb a Buy? Bristol-Myers is a better buy than Eli Lilly for one major reason: its resources.
The Motley Fool June 5, 2009 Brian Orelli	Failure! Merck said today that rolofylline failed to show an effect in its phase 3 clinical trial in heart failure patients.
The Motley Fool June 30, 2010 Brian Orelli	Which Midsized Biotech Is the Best Buy? Biogen Idec, Amgen, or Gilead? Which of these biotechs has the most potential for growth?
The Motley Fool August 5, 2008 Brian Lawler	An ImClone Deal Will Get Done Despite his tough talk, Icahn will likely complete a buyout of ImClone.
The Motley Fool July 24, 2007 Brian Lawler	Biogen's Steady Growth Biogen reports another good quarter of growth, both top- and bottom-line.
The Motley Fool April 25, 2008 Brian Lawler	Biogen's Big Step Forward Pharmaceutical company Biogen IDEC boasts better results and a rosier outlook.
The Motley Fool June 1, 2009 Brian Orelli	Going Up for All the Wrong Reasons Bristol-Myers has been identified as Elan's mystery bidder. So what?
The Motley Fool October 26, 2010 Brian Orelli	Where's the Growth in Big Pharma? The theme for the pharmaceutical industry's 2010 third-quarter earnings reports has been officially set: If you can't get it done through sales, just cut costs.